<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377923</url>
  </required_header>
  <id_info>
    <org_study_id>05A/Prg05</org_study_id>
    <nct_id>NCT00377923</nct_id>
  </id_info>
  <brief_title>Endometrial Effects of Daily Progesterone s.c. 25 and 50 Mg Aqueous Formulation to Female Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <brief_summary>
    <textblock>
      This is a multiple dose, observer blind, randomised, parallel groups pharmacodynamic and
      pharmacokinetic study to assess the endometrial effects (predecidual changes) of a new
      aqueous progesterone formulation administered s.c. at the dose of 25 and 50 mg/day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed in order to assess the efficacy of the investigational product
      (Progesterone acqueous s.c. formulation) when it is administered at the dose of 25 and 50 mg.
      The induced predecidual changes will be evaluated through endometrial bioptic samplings,
      performed on day 11 and will be compared between the two treatment groups.

      The pharmacokinetic evaluation was designed according to internationally recognised
      guidelines for PK studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>partial and full predecidual changes in endometrial samples on the 11th day of exposure to the IMP compared to the findings on the 11th day after ovulation in the menstrual cycle, according to Noyes criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of progesterone at the steady-state following the 25 or 50 mg/day of progesterone s.c. at the time of endometrial biopsy, local tolerability</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI: 19&lt;/=BMI&lt;/=25 kg/m2;

          -  Proper estrogen priming; absence of progesterone exposure prior to exogenous
             progesterone administration;

          -  normal pelvic ultrasound;

          -  absence of active follicular growth following initiation of E2 treatment;

          -  Complete suppression of ovarian function;

          -  Vital signs: SBP 100-139 mmHg, DBP 50-89, HR 50-90 bpm;

          -  Full comprehension of the nature and purpose of the study and possible risks and side
             effects;

          -  signed written informed consent prior to inclusion in the study

        Exclusion Criteria:

          -  pregnant or lactating women;

          -  ECG: clinically relevant abnormalities;

          -  clinical relevant abnormal physical findings which could interfere with the objectives
             of the study;

          -  clinical relevant abnormal laboratory values indicative of physical illness,
             ascertained or presumptive hypersensitivity to the active principle and/or
             formulations' ingredients;

          -  history of anaphylaxis to drugs or allergic reactions in general, which the
             Investigator considers may affect the outcome of the study;

          -  history of uterine pathologies (fibroids, polyps, adenomyosis, etc), history of
             dysfunctional bleeding, relevant history of renal, hepatic, cardiovascular,
             respiratory, skin, haematological, endocrine or neurological diseases, history of
             neoplasias (genital apparatus, breast, liver or hormone-dependent cancer) severe liver
             failure, acute or chronic liver dysfunction, cholestatic jaundice, hypertension,
             thrombo-phlebitis, thrombo-embolism, cerebro-vascular insult or severe depression;
             medication, including OTC, during 2 weeks before the start of the study;

          -  participation in the evaluation of any drug within 1 month prior to the start of the
             study;

          -  blood donations during the 1 month prior to this study;

          -  history of drug, alcohol [&gt;1 drink/day defined according to USDA Dietary Guidelines
             2005 (18)] caffeine (&gt;5 cups/ day of coffee or tea) or tobacco abuse (≥10
             cigarettes/day);

          -  Abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits
             within the past 4 weeks.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Müller, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, AKH, Vienna, Austria.</affiliation>
  </overall_official>
  <reference>
    <citation>de Ziegler D, Bouchard P. Understanding endometrial physiology and menstrual disorders in the 1990s. Curr Opin Obstet Gynecol. 1993 Jun;5(3):378-88. Review.</citation>
    <PMID>8329654</PMID>
  </reference>
  <reference>
    <citation>de Ziegler D, Bergeron C, Cornel C, Medalie DA, Massai MR, Milgrom E, Frydman R, Bouchard P. Effects of luteal estradiol on the secretory transformation of human endometrium and plasma gonadotropins. J Clin Endocrinol Metab. 1992 Feb;74(2):322-31.</citation>
    <PMID>1730810</PMID>
  </reference>
  <reference>
    <citation>NOYES RW, HAMAN JO. Accuracy of endometrial dating; correlation of endometrial dating with basal body temperature and menses. Fertil Steril. 1953 Nov-Dec;4(6):504-17.</citation>
    <PMID>13107761</PMID>
  </reference>
  <reference>
    <citation>Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975 May;122(2):262-3.</citation>
    <PMID>1155504</PMID>
  </reference>
  <reference>
    <citation>Soliman S, Daya S, Collins J, Hughes EG. The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril. 1994 Jun;61(6):1068-76.</citation>
    <PMID>8194619</PMID>
  </reference>
  <reference>
    <citation>Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002 Sep;17(9):2287-99. Review.</citation>
    <PMID>12202415</PMID>
  </reference>
  <reference>
    <citation>Bourgain C, Smitz J, Devroey P. Meta-analysis on luteal phase support. Hum Reprod. 2003 Mar;18(3):656; author reply 656-7.</citation>
    <PMID>12615845</PMID>
  </reference>
  <reference>
    <citation>Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev. 2004;(3):CD004830. Review. Update in: Cochrane Database Syst Rev. 2008;(3):CD004830.</citation>
    <PMID>15266541</PMID>
  </reference>
  <reference>
    <citation>de Ziegler D, Cornel C, Bergeron C, Hazout A, Bouchard P, Frydman R. Controlled preparation of the endometrium with exogenous estradiol and progesterone in women having functioning ovaries. Fertil Steril. 1991 Nov;56(5):851-5.</citation>
    <PMID>1936317</PMID>
  </reference>
  <reference>
    <citation>Lelaidier C, de Ziegler D, Gaetano J, Hazout A, Fernandez H, Frydman R. Controlled preparation of the endometrium with exogenous oestradiol and progesterone: a novel regimen not using a gonadotrophin-releasing hormone agonist. Hum Reprod. 1992 Nov;7(10):1353-6.</citation>
    <PMID>1291558</PMID>
  </reference>
  <reference>
    <citation>Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol. 1997 Sep;90(3):396-401.</citation>
    <PMID>9277651</PMID>
  </reference>
  <reference>
    <citation>Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998 Jan;69(1):96-101.</citation>
    <PMID>9457941</PMID>
  </reference>
  <reference>
    <citation>Jobanputra K, Toner JP, Denoncourt R, Gibbons WE. Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles. Fertil Steril. 1999 Dec;72(6):980-4.</citation>
    <PMID>10593367</PMID>
  </reference>
  <reference>
    <citation>Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod. 1997 Nov;12(11):2359-65.</citation>
    <PMID>9436663</PMID>
  </reference>
  <reference>
    <citation>de Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids. 2000 Oct-Nov;65(10-11):671-9. Review.</citation>
    <PMID>11108875</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2006</study_first_posted>
  <last_update_submitted>September 19, 2006</last_update_submitted>
  <last_update_submitted_qc>September 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2006</last_update_posted>
  <keyword>pharmacodynamic and pharmacokinetic study</keyword>
  <keyword>Progesterone</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>Endometrial decidualisation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

